News headlines about Pharmacyclics (NASDAQ:PCYC) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pharmacyclics earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.5566021857433 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

TRADEMARK VIOLATION NOTICE: “Pharmacyclics (PCYC) Getting Somewhat Positive News Coverage, Analysis Finds” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/pharmacyclics-pcyc-getting-somewhat-positive-news-coverage-analysis-finds/1493876.html.

Pharmacyclics Company Profile

Pharmacyclics, Inc is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer.

Receive News & Ratings for Pharmacyclics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.